Neogenomics (NEO) Current Assets (2010 - 2026)

Neogenomics (NEO) has reported Current Assets for 17 consecutive years, with $373.7 million the latest figure, recorded in Q1 2026.

• Current Assets for Q1 2026 came in at $373.7 million, down 34.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $373.7 million (down 34.89% YoY), and the FY2025 annual result was $376.3 million, down 36.87% from the prior year.
• Current Assets was $373.7 million for Q1 2026 at Neogenomics, down from $376.3 million in the prior quarter.
• Over five years, Current Assets peaked at $651.1 million in Q1 2022 and troughed at $373.7 million in Q1 2026.
• Average Current Assets over 5 years is $545.8 million, with a median of $585.0 million recorded in 2023.
• Year-over-year, Current Assets rose 0.56% in 2024 and sank 36.87% in 2025.
• Over 5 years, Current Assets stood at $605.3 million in 2022, then decreased by 1.4% to $596.8 million in 2023, then decreased by 0.13% to $596.0 million in 2024, then tumbled by 36.87% to $376.3 million in 2025, then slipped by 0.69% to $373.7 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $373.7 million in Q1 2026, $376.3 million in Q4 2025, and $382.5 million in Q3 2025.